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Abstract
Primary immunodeficiency disorder (PID) refers to a heterogeneous group of over 130 disorders that result from
defects in immune system development and/or function. PIDs are broadly classified as disorders of adaptive
immunity (i.e., T-cell, B-cell or combined immunodeficiencies) or of innate immunity (e.g., phagocyte and
complement disorders). Although the clinical manifestations of PIDs are highly variable, most disorders involve at
least an increased susceptibility to infection. Early diagnosis and treatment are imperative for preventing significant
disease-associated morbidity and, therefore, consultation with a clinical immunologist is essential. PIDs should be
suspected in patients with: recurrent sinus or ear infections or pneumonias within a 1 year period; failure to thrive;
poor response to prolonged use of antibiotics; persistent thrush or skin abscesses; or a family history of PID.
Patients with multiple autoimmune diseases should also be evaluated. Diagnostic testing often involves
lymphocyte proliferation assays, flow cytometry, measurement of serum immunoglobulin (Ig) levels, assessment of
serum specific antibody titers in response to vaccine antigens, neutrophil function assays, stimulation assays for
cytokine responses, and complement studies. The treatment of PIDs is complex and generally requires both
supportive and definitive strategies. Ig replacement therapy is the mainstay of therapy for B-cell disorders, and is
also an important supportive treatment for many patients with combined immunodeficiency disorders. The
heterogeneous group of disorders involving the T-cell arm of the adaptive system, such as severe combined
immunodeficiency (SCID), require immune reconstitution as soon as possible. The treatment of innate
immunodeficiency disorders varies depending on the type of defect, but may involve antifungal and antibiotic
prophylaxis, cytokine replacement, vaccinations and bone marrow transplantation. This article provides a detailed
overview of the major categories of PIDs and strategies for the appropriate diagnosis and management of these
rare disorders.
Introduction
Primary immunodeficiency disorder (PID) refers to a het-
erogeneous group of disorders characterized by poor or
absent function in one or more components of the
immune system. Over 130 different disorders have been
identified to date, with new disorders continually being
recognized [1,2]. Most PIDs result from inherited defects
in immune system development and/or function; however,
acquired forms have also been described [3]. It is impor-
tant to note that PIDs are distinct from secondary immu-
nodeficiencies that may result from other causes, such as
viral or bacterial infections, malnutrition, or treatment
with drugs that induce immunosuppression.
With the exception of immunoglobulin A (IgA) defi-
ciency, PIDs are rare; the estimated prevalence of these
disorders in the United States is approximately 1 in
1200 live births. IgA deficiency is the most common
PID, occurring in approximately 1 in 300 to 1 in 500
persons [4].
The clinical presentation of PIDs is highly variable;
however, most disorders involve increased susceptibility
to infection. In fact, many PIDs present as “routine”
infections (often of the sinuses, ears and lungs) and,
therefore, may go undetected in the primary-care set-
ting. The accurate and timely diagnosis of these disor-
ders requires a high index of suspicion and specialized
testing. Therefore, consultation with a clinical immunol-
ogist who is experienced in the evaluation and manage-
ment of immunodeficiencies is essential, since early
diagnosis and treatment are critical for preventing sig-
nificant disease-associated morbidity and improving
patient outcomes [5-7]. This article provides an over-
view of the major categories of PIDs as well as strategies
for the timely identification, diagnosis and management
of these disorders.
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PIDs are broadly classified according to the component
of the immune system that is primarily disrupted: adap-
tive or innate immunity (see An Introduction to Immu-
nology and Immunopathology in this supplement for
more information on adaptive and innate immunity).
Table 1 presents a select list of PIDs grouped according
to this system [5,8].
Disorders of adaptive immunity
T cells and B cells are the primary cells of the adaptive
immune system. B cells mediate antibody production and,
therefore, play a major role in antibody-mediated
(humoral) immunity. T cells, on the other hand, govern
cell-mediated immune responses. Defects occurring at any
stage of T-cell development, differentiation and
maturation lead to T-cell (cellular) immunodeficiency dis-
orders, while defects relating to B-cell development and/or
maturation result in B-cell (antibody-deficiency) disorders.
Since B-cell-mediated antibody production requires intact
T-cell function, most T-cell defects lead to combined (B-
and T-cell) immunodeficiency disorders (CIDs) [3,5].
Disorders of innate immunity
Innate immune responses represent the first line of
defense against potentially invading organisms. Appro-
priate recognition of threats and induction of the
inflammatory cascade are essential steps in the removal
of these organisms from the system. Failure of the
innate system to identify pathogens delays the induction
of the immune response and may worsen outcomes of
infection.
Table 1 Classification of PIDs: examples and typical clinical presentations [5,8]
Classification and examples Clinical presentation
Disorders of adaptive immunity
T-cell (cellular) immunodeficiency
► IFN-g/IL-12
► AIRE mutations
Atypical mycobacterial and salmonella infections
Mucocutaneous candidiasis (thrush) and autoimmune endocrinopathy
B-cell (antibody-mediated) immunodeficiency
► XLA
► CVID
► Selective IgA deficiency
► Specific antibody deficiency
► IgG subclass deficiency
Recurrent sinopulmonary infections with encapsulated bacteria
Autoimmune disease and increased risk of malignancy in CVID
CID
► Wiskott-Aldrich syndrome Thrombocytopenia with bleeding and bruising; eczema; recurrent bacterial and viral
infections; autoimmune disease
► Ataxia telangiectasia Chronic sinopulmonary disease; cerebellar ataxia (difficulty with control of movement); small,
dilated blood vessels of the eyes and skin; malignancy
► DiGeorge syndrome Hypoparathyroidism; seizures; cardiac abnormalities; abnormal facies; infection
► SCID
￿ T
- ,B
+
– gc deficiency
– JAK3 deficiency
￿ T
- ,B
-
– ADA deficiency
– RAG 1/2 deficiency
Severe, recurrent opportunistic infections; failure to thrive; diarrhea; rash
Disorders of innate immunity
Phagocyte defects
► Chronic granulomatous disease
► Hyper IgE syndrome
► Leukocyte adhesion deficiency
Severe infection; abscesses with granuloma formation
Chronic dermatitis; recurrent, severe lung infections; skin infections; bone fragility; failure to shed
primary teeth
Recurrent, severe bacterial infections; poor wound healing; delayed separation of the umbilical
cord
Complement defects
► Deficiency in early complement pathway
components (C1q, C1r, C2, C4)
SLE–like syndrome, rheumatoid disease, multiple autoimmune diseases, infections
► Deficiency in late complement pathway
components (C5, C6, C7, C8, C9)
Neisserial infections, SLE-like syndrome
► C3 and regulatory components Recurrent infections with encapsulated bacteria
AIRE, autoimmune regulator; CVID, common variable immunodeficiency; IgG, immunoglobulin G; IgE, immunoglobulin E; IgA, immunoglobulin A; IFNg, interferon-
gamma; IL, interleukin; CID, combined immunodeficiency; SCID, severe combined immunodeficiency; XLA, X-linked agammaglobulinemia; SLE: systemic lupus
erythematosus; JAK3, Janus kinase 3; ADA, adenosine deaminase; RAG, recombination activating gene
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innate immune response including phagocytes (neutro-
phils and macrophages), dendritic cells, and complement
proteins. Phagocytes are primarily responsible for pha-
gocytosis, the process by which cells engulf and elimi-
nate invading pathogens. Complement proteins function
to identify and opsonize (coat) foreign antigens, render-
ing them susceptible to phagocytosis. Defects in the
development and function of any of these elements of
innate immunity may lead to PIDs.
Clinical presentation
T-cell and combined immunodeficiencies
The clinical manifestations of T-cell (cellular) disorders
and CIDs will vary depending on the specific underlying
defect in the adaptive immune response. Therefore, clin-
ical suspicion is important for timely diagnosis of these
disorders. Patients with specific T-cell defects may be
lymphopenic (i.e., have abnormally low levels of lympho-
cytes) and neutropenic (i.e., have abnormally low levels
of neutrophils). In the most severe forms of CID (also
known as severe combined immunodeficiency [SCID]),
there is a virtual lack of functional T cells and immune
function. These disorders are rare and are generally
categorized into whether there is an absence of T cells,
but presence of B cells (T
– ,B
+), or an absence of both
T and B cells (T
– ,B
–) (see Table 1). Natural killer (NK)
cell numbers are also informative for determining the
genetic phenotype of SCID [3,5]. However, normal T-
cell numbers do not exclude the possibility of T-cell
defects, and in patients with clinical presentations con-
sistent with immunodeficiency, further investigations of
T-cell function are warranted.
Patients with SCID usually present within the first year
of life with chronic diarrhea and failure to thrive; severe,
recurrent infections with opportunistic pathogens (e.g.,
Candida albicans [thrush], Pneumocystis jiroveci, or cyto-
megalovirus); and skin rashes. Some patients may also
have associated neurological defects. SCID is a pediatric
emergency since infection often leads to death and bone
marrow transplantation (BMT) can be curative [3,5].
Other, less severe CIDs that do not characteristically
lead to early mortality include Wiskott-Aldrich syn-
drome, DiGeorge syndrome, ataxia-telangiectasia, and
X-linked lymphoproliferative disease. Patients with these
disorders often present later in childhood with recurrent
infections and clinical findings that vary depending on
the specific syndrome (see Table 1). Autoimmunity and
immune dysregulation are also frequent complications
associated with these CIDs [3,5].
B-cell immunodeficiencies
B-cell (antibody-deficiency) disorders are the most com-
mon type of immunodeficiencies, accounting for
approximately 50% of all PID diagnoses [5]. They com-
prise a heterogeneous group of disorders characterized
by an increased susceptibility to respiratory tract infec-
tions with bacteria, particularly Streptococcus pneumo-
niae and Haemophilus influenzae.
Patients usually present after 6 months of age with
recurrent, and often severe, sinopulmonary infections
such as otitis media, sinusitis, and pneumonia. Diarrhea,
fatigue, autoimmune manifestations (particularly auto-
immune cytopenias), and sensorineural hearing loss are
also common [6,9]. Patients with humoral deficiency
often have reduced or absent serum immunoglobulin
levels, but may also show normal or increased serum
immunoglobulin levels with abnormal function.
More than 20 antibody-deficiency disorders have been
defined to date, however, many remain undefined. Typi-
cal disorders that fall into this category include: X-
linked agammaglobulinemia (XLA; also known as Bru-
ton’s agammaglobulinemia), common variable immuno-
deficiency (CVID), and selective IgA deficiency. XLA
results from a mutation in the Bruton’s tyrosine kinase
(Btk) gene, which is responsible for mediating B-cell
development and maturation. The disorder is character-
ized by markedly reduced levels of circulating B-cells
and serum IgG, IgA and IgM. Affected males usually
present within the first 2 years of life with recurrent
sinopulmonary infections and absent lymph nodes and
tonsils [5,9]. CVID is a heterogeneous disorder charac-
t e r i z e db ym a r k e d l yr e d u c e ds e r u mc o n c e n t r a t i o n so f
IgG, low levels of IgA and/or IgM, and poor or absent
responses to immunization. The disorder affects males
and females equally, and usually has a later age of onset
than other antibody-deficiency disorders (i.e., > 10 years
of age). It is associated with recurrent sinopulmonary
infections, autoimmune and granulomatous disease, gas-
trointestinal complications and an enhanced risk of
malignancy (e.g., lymphoma and gastric carcinoma).
Some patients may also present with bronchiectasis
(irreversible widening of portions of the bronchi result-
ing from damage to the airway wall), which is a com-
mon cause of morbidity and mortality in these patients
[5].
Milder antibody-deficiency disorders, such as selective
IgA deficiency, are associated with variably low serum
levels of an immunoglobulin class or subclass and, in
some cases, impairments in specific antibody formation.
IgA deficiency, for example, is characterized by low or
absent levels of serum IgA in the presence of normal
levels of IgG and IgM. Only about one-third of these
patients are particularly prone to infection [5].
Innate immunodeficiencies
Patients with innate immunodeficiency disorders may
present at any age, often with unusual or difficult to
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phagocyte disorders are severe pyogenic (puss-like) bac-
terial and fungal infections of the skin, respiratory tract,
and internal organs, as well as painful sores around the
mouth. Chronic granulomatous disease (CGD) is a com-
mon phagocyte defect. Hyper-IgE syndrome is another
phagocyte disorder characterized by Staphylococcal
infections of the skin, bone, and lungs, bony abnormal-
ities and high IgE levels. (see Table 1) [3,5,8]. It has
recently been found to result from a mutation in signal
transducer and activator of transcription 3 (STAT3)
which affects phagocytic cell recognition of Staphylococ-
cus as well as osteoclast function involved in bone
remodelling [10].
Of all the PIDs, complement deficiencies account for
less than 1% of identified cases. Patients with these dis-
orders tend to present with systemic autoimmune dis-
ease that resembles lupus erythematosus or with severe
or recurrent infections with encapsulated organisms (see
Table 1) [3,5,8].
Diagnosis
As mentioned previously, early diagnosis of PID is criti-
cal for preventing significant disease-associated morbid-
ity, and even mortality. However, a national survey of
PID in the United States found that more than 40% of
patients with these disorders were not diagnosed until
adulthood (Figure 1A), despite the fact that many
reported serious or chronic health conditions prior to
diagnosis, such as sinusitis, bronchitis, and pneumonia
(see Figure 1B) [11]. The importance of prompt recogni-
tion and management of PIDs is further highlighted by
the rate of hospitalizations pre- and post diagnosis.
Although 70% reported being hospitalized prior to diag-
nosis (Figure 1C), nearly half (48%) reported no hospita-
lization since diagnosis (Figure 1D).
A diagnosis of PID should be suspected in both chil-
dren and adults who have recurrent pneumonias and/or
ear, sinus and cutaneous infections as listed in Table 2.
Although this Table does not provide a comprehensive
list of all signs and symptoms of PID, patients meeting
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Figure 1 Results from the Immune Deficiency Foundation (IDF) national survey of PIDs [11]
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clinical immunologist for further evaluation [7,12]. The
immunologist will perform a comprehensive immune
evaluation that often begins with a complete blood
count (CBC) and blood smear. These tests are used to
evaluate for the presence of lymphopenia, abnormal or
unusual lymphocytes or phagocytic cells, and any asso-
ciated gross hematologic abnormalities that may be indi-
cative of PIDs. Significant lymphopenia, for example,
may be the first indication of T-cell (cellular) immuno-
deficiency. Other important diagnostic tools include
lymphocyte proliferation assays and flow cytometry
which allow for the enumeration of B-cells, T-cells, and
NK, and the evaluation of lymphocyte markers, T-cell
variability, and adhesion receptors that may be asso-
ciated with specific immune defects. Standard flow cyto-
metry analysis is abnormal in most cases of SCID and in
many cases of CID [6,13].
The initial evaluation of patients with suspected B-cell
(antibody-deficiency) disorders involves the measure-
ment of serum IgG, IgA, IgM, and IgE levels (note that
the measurement of IgD is not useful for the diagnosis
of PIDs). Serum levels that are clearly below age-
appropriate reference values may be indicative of B-cell
immunodeficiencies. However, some patients with these
disorders have normal or only modestly reduced immu-
noglobulin levels; therefore, the best approach for con-
firming a diagnosis of an antibody-deficiency disorder is
t h em e a s u r e m e n to fs e r u ms p e c i f i ca n t i b o d yt i t e r s
(usually IgG) in response to vaccine antigens. This
approach involves immunizing a patient with protein
antigens (e.g., tetanus toxoid) and polysaccharide anti-
gens (e.g., pneumococcus) and assessing pre- and post-
immunization antibody levels. In many PIDs, antibody
responses to these antigens are diminished or even
absent [6].
Neutrophil function assays (e.g., dihydrorhodamine
response [DHR]) and stimulation assays for cytokine
responses are helpful for confirming a diagnosis of
innate disorders. For example, abnormal neutrophil oxi-
dase function is usually indicative of CGD. Complement
studies, which examine the level and/or function of spe-
cific complement proteins, are essential for the diagnosis
of complement deficiency disorders. These studies
should be performed by accredited laboratories that
have demonstrated competence in these assays and
experience in performing investigations into PID [5,6].
In some cases, more advanced testing involving spe-
cialized molecular methods may be required to confirm
a diagnosis of PID [13]. Once the diagnosis is estab-
lished, it is important that therapy be initiated as soon
as possible, since delays can lead to permanent organ
damage or even death from overwhelming infection [5].
Treatment
The treatment of PIDs is complex and generally involves
both supportive and definitive strategies (see Table 3).
As such, therapy should be coordinated by an
Table 2 The Jeffrey Modell Foundations’ 10 warning
signs of immune deficiency. [12]
1. ≥ 8 new ear infections with in 1 year.
2. ≥ 2 serious sinus infections within 1 year.
3. ≥ 2 months on antibiotics with little effect.
4. ≥ 2 pneumonias with in 1 year.
5. Failure of an infant to gain weight or grow normally.
6. Recurrent, deep skin or organ abscesses.
7. Persistent thrush in mouth or elsewhere on skin, after age 1.
8. Need for intravenous antibiotics to clear infections.
9. ≥ 2 deep-seated infections.
10. A family history of PID.
Table 3 Strategies for the treatment and management of PIDs
Supportive Definitive
CIDs/SCID ► Ig replacement therapy (IV or SC)
► Antibiotic prophylaxis
► Antifungal prophylaxis
► Aggressive management of established infections
► Infectious precautions when hospitalized
► Withhold all live vaccines
► BMT
► HSCT
► Gene therapy a possibility for some SCIDs
B-cell disorders ► Ig replacement therapy (IV or SC)
► Antibiotic prophylaxis
► Antifungal prophylaxis depending upon etiology
► Hearing assessment
► Assessment of pulmonary status and function
► Close monitoring for co-morbidities
► Gene therapy is a potential future treatment in some patients
Innate disorders ► Antibiotic prophylaxis
► Antifungal prophylaxis
► Cytokine replacement (IFNg) for CGD
► Vaccinations (e.g., meningococcal)
► Ig replacement is sometimes indicated
► BMT, e.g., for CGD
► Gene therapy is a potential future treatment
Ig, immunoglobulin; IV: intravenous; SC, subcutaneous; CID, combined immunodeficiency; SCID, severe combined immunodeficiency; IFNg, interferon-gamma;
BMT, bone marrow transplantation; CGD, chronic granulomatous disease; HSCT, hematopoietic stem cell transplantation
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these disorders [5,7].
SCID/CID
Initial therapy for patients with SCID or other CIDs is
supportive and involves aggressive management of the
established infection, immunoglobulin (Ig) replacement
therapy (discussed in more detail in the next section),
and antibiotic and antifungal prophylaxis to reduce the
frequency and severity of infections. There is currently
no standardized approach to the use of prophylactic
antibiotics in patients with established PIDs since rando-
mized, controlled studies in this area are lacking. Com-
monly used regimens are derived from studies focusing
on the prevention of otitis media in children and
include: sulfisoxazole, amoxicillin, trimethoprim-sulfa-
methoxazole (TMP-SMX) and azithromycin [3,5].
Patients with SCID should also be protected from expo-
sure to infectious agents. In the hospital setting, protec-
tive isolation in positive pressure rooms is
recommended. Furthermore, live attenuated vaccines (e.
g., such measles/mumps/rubella/varicella, bacillus Calm-
ette-Guerin, infant rotavirus, and oral polio virus) are
contraindicated in patients with SCID as they can lead
to severe, disseminated and fatal infections [5]. There is
no risk of disseminated infections from killed or inacti-
vated vaccines and, therefore, these may be administered
according to routine indications and schedules in
patients with PIDs [5].
Since SCID is fatal unless the underlying defect is cor-
rected, definitive therapy with BMT or hematopoietic
stem cell transplantation (HSCT) should be initiated as
quickly as possible. When performed from a human leu-
kocyte antigen (HLA)-identical sibling, these procedures
lead to excellent long-term survival and long-lasting
immune reconstitution. Good results have also been
obtained with HLA-mismatched related donors when
the procedures are performed within the first 3.5
months of life; however, less satisfactory outcomes have
been noted in older patients [3,5]. Gene therapy, which
involves introducing a functional copy of the patient’s
defective gene into appropriate cells, has also been
shown to lead to immune reconstitution and improved
survival in patients with certain SCIDs, such as adeno-
sine deaminase (ADA) deficiency and SCID-X1 (an X-
linked inherited SCID characterized by an early block in
T-cell differentiation) [14]. Enzyme replacement therapy
with weekly intramuscular injections of pegylated bovine
ADA is also available for the management of patients
with ADA deficiency [3].
B-cell immunodeficiencies
The mainstay of therapy for most B-cell (antibody-defi-
ciency) disorders is intravenous (IV) or subcutaneous Ig
replacement therapy; in fact, many patients will require
this treatment indefinitely. There are currently five Ig
replacement products approved for the treatment of
PID in Canada (see Table 4). IV and subcutaneous for-
mulations are considered equally effective in reducing
the frequency and severity of infections, and there is
insufficient evidence to sug g e s tt h a to n ep r o d u c ti s
superior to another [3,7]. When deciding on a specific
product, patient preference should be taken into consid-
eration. Some patients may prefer a subcutaneous for-
mulation since therapy can be administered at home.
Note that intramuscular Ig replacement therapy is not
considered to be as effective as IV or subcutaneous ther-
apy and, therefore, is not recommended for the treat-
ment of PID [7].
The recommended starting dose of Ig replacement
therapy is 400–600 mg/kg/4 weeks for the IV formula-
tion and 100–150 mg/kg/week for the subcutaneous for-
mulation [7]. The most common adverse events
associated with this therapy are headache, flushing,
chills, myalgia, wheezing, tachycardia, lower back pain,
nausea, and hypotension. In patients experiencing multi-
ple adverse reactions to one product, consideration may
be given to switching to another product or route of
administration [7].
For patients with recurrent infections, prophylactic
antibiotic therapy (particularly with agents that provide
coverage of Streptococcus pneumoniae and Haemophilus
influenzae) may also be needed in addition to Ig repla-
cement therapy. Depending on the etiology of the speci-
fic B-cell disorder, prophylactic antifungal therapy may
also be required. Since B-cell immunodeficiencies are
often associated with sensorineural hearing loss and pul-
monary complications, regular hearing assessments and
monitoring of pulmonary status and function is recom-
mended. As with primary T-cell defects, vigilance for
malignancies and autoimmune disorders is also impor-
tant in patients with B-cell disorders.
At present, there are no definitive management strate-
gies that can be routinely recommended for patients
with B-cell disorders. However, gene therapy is currently
being investigated for some antibody deficiencies and
may represent a future treatment option for these
patients [14].
Innate disorders
The management of innate disorders depends on the
type of defect. For phagocyte disorders, therapy is pri-
marily supportive and includes both antibiotic and anti-
fungal prophylaxis. Cytokine replacement (e.g.,
interferon-gamma) and BMT have also been shown to
be effective in patients with CGD. Gene therapy may
also be a potential definitive treatment option in the
future [5,14].
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deficiencies. Treatment of these disorders focuses on
antibiotic prophylaxis for the prevention of recurrent
infections. Since some patients with complement disor-
ders are at increased risk of meningococcal infections
with Neisseria meningitidis, multivalent meningococcal
vaccinations should also be considered. Pneumococcal
and Haemophilus influenzae vaccines may also be
needed in patients with frequent infections caused by
encapsulated organisms.
Prognosis
The prognosis of patients with PIDs varies depending on
the etiology of the disorder. However, patient outcomes
and long-term survival have improved significantly since
the 1970s given our improved management of infections
and early access to antibiotics, advances in BMT and
HSCT techniques, and enhanced intensive care services.
Furthermore, routine vaccinations provide herd immu-
nity to those at risk, decreasing the circulation of infec-
tious disease. Further progress in the diagnosis and
management of PIDs is expected as research on the
genes responsible for immunodeficiencies and the use of
definitive treatments such as gene therapy continues.
Conclusions
PID refers to a heterogeneous group of disorders that
result from defects in immune system development and/
or function. Although the signs and symptoms of PIDs
are highly variable, most disorders involve increased sus-
ceptibility to infection, with many leading to significant
disease-associated morbidity and mortality. Given the
complexity of these disorders, referral to an immunolo-
gist is required for appropriate diagnosis and manage-
ment. Severe disorders such as SCID requires definitive
therapy for immune reconstitution (e.g., BMT, HSCT)
as soon as possible. B-cell or antibody-deficiency disor-
ders are the most common types of PIDs. The mainstay
of treatment for patients with these disorders is Ig repla-
cement therapy. Patients with innate immunodeficiency
disorders often present with unusual or difficult to era-
dicate infections. Treatment varies depending on the
type of defect (e.g., phagocyte disorder or complement
deficiency), but may involve antifungal and antibiotic
prophylaxis, cytokine replacement, vaccinations and
BMT.
Key take-home messages
► With the exception of IgA deficiency (prevalence = 1
in 300-500), PIDs are more frequent than previously
believed, with an estimated prevalence of 1 in 1200.
► Clinical presentation is highly variable, but most dis-
orders involve increased susceptibility to infection.
► PIDs should be suspected in patients with: recurrent
sinus or ear infections or pneumonias within a 1 year
period; failure to thrive; poor response to prolonged use
of antibiotics; persistent thrush or skin abscesses; or a
family history of PID.
Table 4 Ig replacement therapies for PID approved in Canada [7]
Gammagard S/D,
(Baxter)
Gamunex/
IGIVnex, Talecris
(Biotherapeutics)
Gammagard Liquid, (Baxter) Privigen CSL,
(Behring
Canada)
Vivaglobin CSL, (Behring
Canada)
Formulation Lyophilized Liquid Liquid Liquid Liquid
Administration IV IV IV IV SC
Concentration 5% or 10% upon
reconstitution
9%-11% 9%-11% 10% 16%
Shelf-life Not specified 36 months 36 months Not specified 24 months
Storage
requirements
Up to 25°C
Do not freeze
2°C-8°C (36 mo),
up to 25°C (6 mo)
Do not freeze
2°C-8°C (36 mo), up to 25°C (for a
single period of up to 9 mo within
the first 24 mo from date of
manufacture)
Do not freeze
Room
temperature
(up to 25°C)
Do not freeze
Keep in the
original carton
to protect it
from light
2-8°C (24 mo)
Do not freeze
Keep vials in storage box
until use
Do not administer if vial has
been opened more than 4 h
Infusion rate
and dosage
For 5% solution:
4 mL/kg/h, maximum
(3.3 mg/kg/min,
maximum)
For 10% solution:
8 mL/kg/h, maximum
(calculated rate:13.3
mg/kg/min,
maximum)
0.14 mL/kg/min
(14 mg/kg/min,
maximum)
8 mL/kg/h
maximum (calculated rate: 13.3 mg/
kg/min, maximum)
0.08 mL/kg/
min, maximum
(8 mg/kg/min)
100-200 mg/kg weekly;
maximum volume of 15 mL
per injection site at a rate of
20 mL/h
Previous IV Ig dose ×1.37,
then divide into weekly dose
based on previous IV Ig
interval
IV: intravenous; SC: subcutaneous
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required to confirm the diagnosis of PID and to estab-
lish an appropriate treatment plan.
► SCID is fatal unless the underlying defect is cor-
rected and, therefore, definitive therapy with BMT or
HSCT should be initiated as quickly as possible.
► Ig replacement therapy is the mainstay of therapy
for antibody-deficiency disorders, and is also an impor-
tant supportive treatment for many patients with other
forms of PID including SCID/CID.
► Antibiotic and antifungal prophylaxis are also
recommended for many PIDs to prevent the frequency
and severity of infections.
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